| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 19
| Issue : 2 | Page : 110-114 |
|
|
Amitriptyline in irritable bowel syndrome: A clinical review
Mani Rajagopalan1, Ashray Rajagopalan2, Ashwin Rajagopalan3
1 Consultant Psychiatrist, Ballarat, Victoria, Australia
2 Monash Health, Monash University, Clayton, Victoria, Australia
3 Monash School of Medicine, Monash University, Clayton, Victoria, Australia
Correspondence Address:
Dr. Mani Rajagopalan
24 Drummond Street North, Ballarat VIC 3350
Australia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/cmi.cmi_13_21
|
|
|
Irritable bowel syndrome is the most common functional gastrointestinal disorder in the primary care setting. Symptoms tend to be long lasting and patients have been reported to have a higher prevalence of psychological distress. Antidepressants have been shown to be effective in its management and we review trials involving amitriptyline. Possible mechanisms of action are discussed.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
